A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

Tennis legend Serena Williams, throughout her illustrious career, has consistently defied conventional notions of femininity ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing cancer risk among patients with obesity, particularly for endometrial, ovarian, and meningioma cancers.

New research reveals that GLP-1 receptor agonists significantly lower mortality risk in older cancer patients with type 2 ...

Most people have likely heard about the new weight-loss and diabetes management drugs called Ozempic and Mounjaro, which are ...

Employers explore glucagon-like peptide-1 (GLP-1) therapies' impact on health benefits, showcasing accountability and ...

Serena Williams has revealed that she's taking a GLP-1 injectable weight loss treatment, in addition to her health regimen.

Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...

People with obesity who take weight loss and diabetes drugs like Ozempic and Mounjaro could face a lower risk of cancer compared to those with obesity who do not. Looking at 14 cancers, of which 13 ...

This retrospective cohort study found that taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) was associated with a reduced overall risk of cancer, including lower risks of endometrial, ...

A new imaging approach reveals how dual agonist drugs like tirzepatide act on the pancreas and brain to regulate blood sugar and appetite.